Profile data is unavailable for this security.
About the company
Nanjing Vazyme Biotech Co Ltd is China-based company principally engaged in biopharmaceuticals. The Company's main business is the technology research and development and product development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. The Company's products include polymerase chain reaction (PCR), reverse transcription, gene sequencing series and other biological reagent products, quantum dot immunofluorescence reagents, latex enhanced immune turbidity reagents and colloidal gold immunochromatography reagents and other point-of-care testing (POCT) Diagnostic reagents and instruments.
- Revenue in CNY (TTM)1.40bn
- Net income in CNY23.59m
- Incorporated2012
- Employees2.70k
- LocationNanjing Vazyme Biotech Co Ltd1-6F, East Section, Building C1-2Hongfeng Science and Technology ParkKechuang Road, Economic and TechnologicaNANJING 210000ChinaCHN
- Phone+86 2 585771179
- Fax+86 2 585771171
- Websitehttps://www.vazyme.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guangxi Wuzhou Zhongheng Group Co Ltd | 2.86bn | -24.94m | 9.18bn | 2.89k | -- | 1.41 | -- | 3.21 | -0.0074 | -0.0074 | 0.8379 | 1.89 | 0.2476 | 2.17 | 4.52 | 990,180.10 | -0.3138 | 2.26 | -0.4836 | 3.38 | 42.33 | 72.05 | -1.27 | 7.27 | 2.39 | -- | 0.1767 | 45.67 | 14.10 | -1.26 | 6.69 | -32.76 | -4.56 | -30.12 |
| Shenzhen Chipscreen Biosciences Co Ltd | 656.24m | -70.33m | 9.45bn | 1.06k | -- | 5.75 | -- | 14.40 | -0.1709 | -0.1709 | 1.60 | 4.03 | 0.2022 | 2.34 | 4.47 | 620,847.90 | -2.17 | 1.32 | -2.44 | 1.54 | 86.24 | 93.29 | -10.72 | 6.97 | 2.76 | -0.5584 | 0.441 | 0.00 | -1.18 | 28.81 | 408.09 | 23.31 | 10.23 | -- |
| North China Pharmaceutical Co Ltd | 9.71bn | 79.38m | 9.63bn | 10.16k | 120.57 | 1.79 | -- | 0.9917 | 0.0465 | 0.0465 | 5.68 | 3.13 | 0.4492 | 2.67 | 4.34 | 955,385.00 | 0.6731 | -0.2978 | 1.54 | -0.7042 | 29.79 | 35.73 | 1.50 | -0.5985 | 0.5609 | 1.64 | 0.6482 | -- | -3.62 | 1.89 | 100.71 | -49.62 | 4.22 | -19.73 |
| GuangYuYuan Chinese Herbal Medicn Co Ltd | 1.24bn | 136.56m | 9.64bn | 1.81k | 70.58 | 6.15 | -- | 7.77 | 0.279 | 0.279 | 2.53 | 3.20 | 0.5011 | 0.5647 | 2.60 | 684,557.40 | 6.04 | -2.10 | 8.71 | -3.16 | 72.21 | 69.74 | 12.05 | -6.00 | 0.9873 | 21.00 | 0.0267 | -- | 13.56 | -4.53 | 136.03 | -24.78 | -58.35 | -- |
| Harbin Pharmaceutical Group Co., Ltd. | 16.22bn | 613.05m | 9.72bn | 9.85k | 15.96 | 1.87 | -- | 0.5994 | 0.2418 | 0.2418 | 6.38 | 2.07 | 1.15 | 6.29 | 3.47 | 1,646,115.00 | 4.78 | 0.7414 | 12.56 | 1.89 | 27.60 | 23.87 | 4.15 | 0.7294 | 1.11 | 36.80 | 0.3633 | 0.00 | 11.93 | 7.41 | -14.88 | 2.69 | -5.38 | -- |
| Youcare Pharmaceutical Group Co Ltd | 4.23bn | 242.25m | 9.86bn | 3.18k | 40.73 | 2.69 | -- | 2.33 | 0.5382 | 0.5382 | 9.39 | 8.14 | 0.7221 | 2.33 | 5.37 | 1,330,727.00 | 4.11 | 7.11 | 6.04 | 11.65 | 58.62 | 64.14 | 5.70 | 8.07 | 1.52 | 105.13 | 0.1939 | 60.95 | -7.61 | 1.05 | -44.84 | -7.16 | 23.40 | -- |
| Nanjing Vazyme Biotech Co Ltd | 1.40bn | 23.59m | 10.01bn | 2.70k | 406.79 | 2.51 | -- | 7.14 | 0.0615 | 0.0615 | 3.84 | 9.97 | 0.2644 | 1.06 | 3.57 | 519,483.10 | 0.4122 | 13.16 | 0.5237 | 15.92 | 70.21 | 70.50 | 1.56 | 23.92 | 4.17 | -- | 0.1436 | 32.20 | -63.97 | 49.74 | -111.94 | -- | 48.61 | -- |
| Chongqing Genrix Biophrmctcl Co Ltd | 13.56m | -779.42m | 10.11bn | 547.00 | -- | 4.30 | -- | 745.51 | -2.13 | -2.13 | 0.037 | 6.42 | 0.0039 | 0.1009 | 1.37 | 24,790.27 | -22.22 | -- | -23.06 | -- | 55.87 | -- | -5,747.82 | -- | 18.62 | -- | 0.2454 | -- | 154.92 | -- | -39.03 | -- | -- | -- |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 9.55bn | -34.96m | 10.48bn | 8.06k | -- | 1.27 | -- | 1.10 | -0.0412 | -0.0412 | 8.20 | 6.83 | 0.555 | 3.23 | 4.28 | 1,184,162.00 | -0.3467 | 1.95 | -0.5663 | 3.77 | 39.08 | 40.58 | -0.6248 | 3.43 | 0.6491 | -- | 0.3696 | 26.07 | -13.82 | 0.3618 | -119.05 | -- | -31.58 | -- |
| Mayinglong Pharmaceutical Group Co Ltd | 3.48bn | 482.37m | 10.99bn | 2.88k | 22.79 | 2.75 | -- | 3.16 | 1.12 | 1.12 | 8.08 | 9.28 | 0.6872 | 6.42 | 8.53 | 1,208,299.00 | 9.74 | 10.82 | 11.64 | 13.47 | 44.84 | 41.18 | 14.17 | 14.08 | 4.40 | -- | 0.0936 | 33.04 | -11.20 | 7.38 | -7.46 | 20.26 | 58.33 | 21.67 |
Data as of Nov 22 2024. Currency figures normalised to Nanjing Vazyme Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
9.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Hwabao WP Fund Management Co., Ltd.as of 30 Jun 2024 | 3.83m | 2.30% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 2.55m | 1.53% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 2.41m | 1.45% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2024 | 1.80m | 1.08% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 1.10m | 0.66% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 1.03m | 0.62% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 986.43k | 0.59% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 710.10k | 0.43% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 523.37k | 0.31% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 389.81k | 0.23% |
More ▼
Data from 30 Jun 2024 - 11 Nov 2024Source: FactSet Research Systems Inc.
